
Novo Nordisk has decided to keep a large-scale study investigating the cardiovascular benefits of obesity drug Wegovy (semaglutide) running, which could be to the chagrin of investors who hoped for results sooner rather than later.
In the pharmaceutical firm’s Q2 report from Wednesday, Novo Nordisk says that the external independent Data Monitoring Committee, DMC, recommended that the study continue back in July following a review of interim data. Consequently, the study will run as planned until mid-2023.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app